Brainstorm Cell Therapeutics
BCLI · NASDAQ
$0.80+$0.03 (+3.90%)TodayMarket closed ·
Prev close $0.77
Who owns BCLI
Largest institutional holders, from their latest 13F filings
The 10 largest institutions hold 8.5% of BCLI’s shares.
- Lebovits Chaim1.8%
- Patlis (Alla)1.3%
- Frenkel (Jacob A.)1.3%
- ACC International Holdings, Ltd.1.2%
- Next 6 largest institutions2.9%
- All other shareholders91.5%
| Holder | Shares | % of shares |
|---|---|---|
| Lebovits Chaim | 200.96K | 1.82% |
| Patlis (Alla) | 144.35K | 1.31% |
| Frenkel (Jacob A.) | 143.78K | 1.30% |
| ACC International Holdings, Ltd. | 133.39K | 1.21% |
| Dagher (Ibrahim B.) | 79.52K | 0.72% |
| Yablonka (Uri) | 68.46K | 0.62% |
| Hartounian (Hartoun) | 52.00K | 0.47% |
| Lindborg (Stacy R) | 44.15K | 0.40% |
| Arbel (Irit) | 41.05K | 0.37% |
| Naor (Nir) | 31.47K | 0.29% |
Insider trades
Form 4 filings by officers, directors and large holders
Insiders made no open-market buys or sales of BCLI in the last 6 months.
| Insider | Type | Shares | Value |
|---|---|---|---|
| FRENKEL JACOB A | Award | 100.00K | — |
| Pitts Peter Joe | Award | 900.00K | — |
Short interest
Settled Sep 30, 2026
- Shares short
- 36.46K
- Days to cover
- 1.44
- % of shares outstanding
- 0.33%
- Average daily volume
- 25.30K
- Change since last report
- −14.1%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.